Concortis Biosystems

Concortis Biosystems was a private biotechnology company based in San Diego that developed next-generation biotherapeutics, with a particular focus on antibody-drug conjugates and related conjugation technologies. Its platform aimed to attach small-molecule payloads to biologics to improve efficacy while reducing off-target toxicity. The company focused primarily on oncology and also cited metabolic disease as an area of interest. Publicly available sources indicate that Concortis maintained a preclinical pipeline and was later acquired by Sorrento Therapeutics in 2013. The requested name "Concortis Biotherapeutics" appears to be an alternative branding or descriptive name used for Concortis Biosystems rather than a separate company.